Replies to post #36889 on Revive Therapeutics Ltd (RVVTF)

[ReikoBlack]

I’ve been a shareholder of Revive since mid 2020 so I’ve seen how Revive (Michael Frank) tends to structure it’s Press Releases. Michael Frank is a horrible CEO. I’ve had email interactions with him in 2023 letting him know my disappointment with Revive’s mismanagement over their Bucillamine Phase 3 COVID-19 trial. He actually told me then that i should go talk/argue with the FDA about the difficulty with getting Bucillamine approved. I told him that a poorly designed clinical trial wasn’t the FDA’s fault and the fault for that was on Revive’s management.

Hopefully, things will be different this time with the DRDC taking the lead on the research study.

By the way, i emailed him this before i posted it here. ;) (asking him - "I see a pattern, do you?")
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177384308

Would have to agree with your assessment.....for now at least.

I do however won't complain about the 400%+ gain from the 008$.